Netherlands-based medical robotics company Vitestro has signed an agreement with a healthcare provider OLVG Lab for the supply of its multiple autonomous blood-drawing devices.

The autonomous blood-drawing devices are expected to be delivered to OLVG Lab upon receiving CE mark approval in Europe.

Designed to support consistent blood drawing, the devices are expected to address the growing shortage of healthcare workers.

OLVG Lab director Anja Leyte said: “Vitestro’s technology will improve the standardisation and optimisation of the sampling procedure and it helps solve staff shortages in our blood-drawing department.

“But more importantly, the patients are also very positive. Our staff are really enthusiastic as well and can’t wait to start using this breakthrough technology in our healthcare.”

Since 2018, OLVG Lab has been engaged in the development of autonomous blood-drawing devices.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Both patients and blood-drawing staff at OLVG hospital were assessed with Vitestro’s technology.

Multiple hospitals, laboratories and blood-drawing departments are also planning to use the company’s blood-drawing technology. The delivery of the devices is anticipated to begin in late 2024.

Vitestro co-founder and CEO Toon Overbeeke said: “After more than 5 years of co-creation and development with OLVG Lab, this is a special moment.

“It is a privilege to be the first to place our innovation at OLVG Lab. Together, we will make sure this innovation will become a great success for both employees and patients.”